Novartis Gets A Miss and a Hit in Urticaria Space

By PacConAdmin | December 20, 2021

Ligelizumab, Novartis’ investigational anti-IgE antibody, didn’t stand up to the company’s established blockbuster omalizumab in a pair of phase 3 studies in patients with chronic spontaneous urticaria (CSU).
Source: Drug Industry Daily

Posted in Drug Industry Daily